trial

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCTId NCT01555697
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 80 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2019-06-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
80 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2014-07
Primary completion
2019-06-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Memantine

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Sites

1 total
San Diego, United States

Linked catalysts

1
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia — primary completion2019-06-01

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE1,PHASE2
Primary Completion Date
2019-06-01
Status
COMPLETED
relationships
The graph out of here
drug
Memantine
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizophrenia
indication